Publication: Novel Potential Application of Chitosan Oligosaccharide for Attenuation of Renal Cyst Growth in the Treatment of Polycystic Kidney Disease
Issued Date
2020-11-27
Resource Type
ISSN
14203049
Other identifier(s)
2-s2.0-85097035203
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Molecules (Basel, Switzerland). Vol.25, No.23 (2020)
Suggested Citation
Nutthapoom Pathomthongtaweechai, Sunhapas Soodvilai, Rath Pichyangkura, Chatchai Muanprasat Novel Potential Application of Chitosan Oligosaccharide for Attenuation of Renal Cyst Growth in the Treatment of Polycystic Kidney Disease. Molecules (Basel, Switzerland). Vol.25, No.23 (2020). doi:10.3390/molecules25235589 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/60393
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Novel Potential Application of Chitosan Oligosaccharide for Attenuation of Renal Cyst Growth in the Treatment of Polycystic Kidney Disease
Other Contributor(s)
Abstract
Chitosan oligosaccharide (COS), a natural polymer derived from chitosan, exerts several biological activities including anti-inflammation, anti-tumor, anti-metabolic syndrome, and drug delivery enhancer. Since COS is vastly distributed to kidney and eliminated in urine, it may have a potential advantage as the therapeutics of kidney diseases. Polycystic kidney disease (PKD) is a common genetic disorder characterized by multiple fluid-filled cysts, replacing normal renal parenchyma and leading to impaired renal function and end-stage renal disease (ESRD). The effective treatment for PKD still needs to be further elucidated. Interestingly, AMP-activated protein kinase (AMPK) has been proposed as a drug target for PKD. This study aimed to investigate the effect of COS on renal cyst enlargement and its underlying mechanisms. We found that COS at the concentrations of 50 and 100 µg/mL decreased renal cyst growth without cytotoxicity, as measured by MTT assay. Immunoblotting analysis showed that COS at 100 µg/mL activated AMPK, and this effect was abolished by STO-609, a calcium/calmodulin-dependent protein kinase kinase beta (CaMKKβ) inhibitor. Moreover, COS elevated the level of intracellular calcium. These results suggest that COS inhibits cyst progression by activation of AMPK via CaMKKβ. Therefore, COS may hold the potential for pharmaceutical application in PKD.